Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is facing constrained near-term visibility and elevated execution risk, leading to a lowering of our rating from Buy to Hold due to limited catalysts and tightening capital resources. While the company has made progress in advancing GEO-MVA and strengthening its intellectual property, the recent $1M registered direct offering highlights potential funding constraints and increases the likelihood of additional dilutive capital raises for the company to advance its pipeline.

Bears say

Geovax Labs is a clinical-stage biotechnology company with a negative outlook, due to the company's high reliance on its GEO-MVA platform, which is in its early stages with no approved products. In addition, the recent reverse stock split and low cash balance increase the risk of future dilution for investors. The company reported a decline in revenue and a net loss in 2025, highlighting its financial challenges and the need for external funding. While there are potential catalysts in the form of clinical progress and new studies, they are unlikely to impact the company's valuation in the near term, leading to a negative outlook.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.